{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-006798","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.230135+00:00","generated_at":"2026-05-23T02:12:33.472604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M","bullets":["Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).","Net loss widened to $(9.1)M in FY2024 from $(8.0)M, driven by NAYA Therapeutics merger costs.","Adjusted EBITDA improved to $(2.2)M in FY2024 from $(4.9)M in FY2023.","Company announced intent to divest majority stake in NAYA TX to refocus on fertility clinic operations.","Management cites declining U.S. fertility rate and rising ART demand as expansion catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-006798","json":"https://secwatch.observer/filing/0001641172-25-006798.json","markdown":"https://secwatch.observer/filing/0001641172-25-006798.md","text":"https://secwatch.observer/filing/0001641172-25-006798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/0001641172-25-006798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:12:33.472604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}